[HTML][HTML] Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes
I Russo, CG Brookles, C Barale, E Melchionda… - International Journal of …, 2024 - mdpi.com
The role of antiplatelet therapy in patients with acute coronary syndromes is a moving target
with considerable novelty in the last few years. The pathophysiological basis of the treatment …
with considerable novelty in the last few years. The pathophysiological basis of the treatment …
Differential impact of clinical factors for predicting high platelet reactivity on clinical outcomes in acute myocardial infarction patients treated with clopidogrel and …
H Goto, Y Saito, T Matsumoto, T Sato… - … of Atherosclerosis and …, 2023 - jstage.jst.go.jp
Aims: Several scoring systems, including the ABCD-GENE and HHD-GENE scores
incorporating clinical and genetic factors, have been developed to identify patients likely to …
incorporating clinical and genetic factors, have been developed to identify patients likely to …
[HTML][HTML] Antiplatelet strategies following PCI: A review of trials informing current and future therapies
Dual antiplatelet therapy (DAPT) has been paramount in preventing thrombosis following
percutaneous coronary intervention for nearly 3 decades. However, over the years, DAPT …
percutaneous coronary intervention for nearly 3 decades. However, over the years, DAPT …
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine
F Gragnano, A Capolongo, F Terracciano… - Expert Review of …, 2023 - Taylor & Francis
Introduction Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is a
cornerstone in the treatment of patients with acute coronary syndrome (ACS) undergoing …
cornerstone in the treatment of patients with acute coronary syndrome (ACS) undergoing …
[HTML][HTML] CYP2C19 loss-of-function alleles predicts clinical outcomes in East Asian patients with acute myocardial infarction undergoing percutaneous coronary …
YW Chen, YJ Liao, WC Chang, TH Hsiao… - Frontiers in …, 2022 - frontiersin.org
Background CYP2C19 loss-of-function (LOF) alleles reduce the effectiveness of clopidogrel
and are associated with high rates of clinical events in patients undergoing percutaneous …
and are associated with high rates of clinical events in patients undergoing percutaneous …
Safety and efficacy of selective, clopidogrel-based strategies in acute coronary syndrome: a study-level meta-analysis
G Patti, L Grisafi, EG Spinoni… - Thrombosis and …, 2022 - thieme-connect.com
Objectives To investigate outcomes with selective, clopidogrel-based therapies versus
conventional treatment in patients undergoing percutaneous coronary intervention (PCI) …
conventional treatment in patients undergoing percutaneous coronary intervention (PCI) …
Demystifying the Contemporary Role of 12-Month Dual Antiplatelet Therapy After Acute Coronary Syndrome
For almost two decades, 12-month dual antiplatelet therapy (DAPT) in acute coronary
syndrome (ACS) has been the only class I recommendation on DAPT in American and …
syndrome (ACS) has been the only class I recommendation on DAPT in American and …
Gender differences in efficacy and safety of antiplatelet strategies for acute coronary syndromes
G Occhipinti, A Greco, DJ Angiolillo… - Expert Opinion on …, 2023 - Taylor & Francis
Introduction Dual antiplatelet therapy (DAPT) represents the cornerstone of secondary
prevention in patients presenting with acute coronary syndrome (ACS) and undergoing …
prevention in patients presenting with acute coronary syndrome (ACS) and undergoing …
Reduced mortality with antiplatelet therapy deescalation after percutaneous coronary intervention in acute coronary syndromes: a meta-analysis
T Palmerini, AG Bruno, M Gasparini… - Circulation …, 2022 - Am Heart Assoc
Background: Antiplatelet therapy deescalation has been suggested as an alternative to
standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding …
standard treatment with potent dual antiplatelet therapy (DAPT) for 1 year in low bleeding …
Antiplatelet De-Escalation Strategies in Patients Undergoing Percutaneous Coronary Intervention
A Spirito, SL Krishnan, D Capodanno… - Circulation …, 2024 - Am Heart Assoc
Dual antiplatelet therapy—the combination of aspirin and a P2Y12 inhibitor—remains the
standard antiplatelet regimen recommended to prevent ischemic complications immediately …
standard antiplatelet regimen recommended to prevent ischemic complications immediately …